6660 — AIM Vaccine Co Share Price
0.000.00%
Last trade - 00:00- HK$9.99bn
- HK$11.40bn
- CNY1.19bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.43 | ||
| PEG Ratio (f) | 0.11 | ||
| EPS Growth (f) | 622.57% | ||
| Dividend Yield (f) | 2.12% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.54 | ||
| Price to Tang. Book | 3.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.78% | ||
| Return on Equity | -30.25% | ||
| Operating Margin | -187.53% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 951.65 | 1,637.97 | 1,570.13 | 1,264.07 | 1,187.47 | 3,407.85 | 4,673.76 | 5.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +216.63 | n/a | n/a | n/a | n/a | +90.38 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AIM Vaccine Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of vaccine. The Company's products mainly include recombinant hepatitis B vaccine, human rabies vaccine, inactivated hepatitis A vaccine, mumps vaccine, inactivated hemorrhagic fever with renal syndrome vaccine and MPSV4. The Company's products are mainly used for the treatment of hepatitis B, hepatitis A, mumps, hemorrhagic fever with renal syndrome, rabies and meningococcal diseases. The Company's vaccine candidates include messenger RNA (mRNA) corona virus disease 2019 (COVID-19) vaccine, inactivated COVID-19 vaccine, broad-spectrum COVID-19 vaccine, PCV13, PPSV23 and MCV4. The Company principally conducts its businesses in the domestic market.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 9th, 2011
- Public Since
- October 6th, 2022
- No. of Employees
- 1,624
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,211,062,599
- Address
- 25/F, BEIJING, 110000
- Web
- https://www.aimbio.com/
- Phone
- +86 1085950621
- Auditors
- Ernst & Young
Upcoming Events for 6660
Similar to 6660
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Co
Stock Exchange of Hong Kong Limited
FAQ
What is the AIM Vaccine Co share price?
As of Today at 19:00 UTC, shares in AIM Vaccine Co are trading at HK$8.25. This share price information is delayed by 15 minutes.
How has the AIM Vaccine Co share price performed this year?
Shares in AIM Vaccine Co last closed at HK$8.25 and the price had moved by -80.59% over the past 365 days. In terms of relative price strength the AIM Vaccine Co share price has underperformed the FTSE Developed Asia Pacific Index by -79.74% over the past year.
What are the analyst and broker recommendations for AIM Vaccine Co?
The overall consensus recommendation for AIM Vaccine Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the AIM Vaccine Co dividend yield?
AIM Vaccine Co does not currently pay a dividend.
Does AIM Vaccine Co pay a dividend?
AIM Vaccine Co does not currently pay a dividend.
When does AIM Vaccine Co next pay dividends?
AIM Vaccine Co does not currently pay a dividend.
How do I buy AIM Vaccine Co shares?
To buy shares in AIM Vaccine Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AIM Vaccine Co?
As of the previous close price of HK$8.25, shares in AIM Vaccine Co had a market capitalisation of HK$9.99bn.
Where are AIM Vaccine Co shares listed?
Here are the trading details for AIM Vaccine Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6660
What kind of share is AIM Vaccine Co?
Based on an overall assessment of its quality, value and momentum AIM Vaccine Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AIM Vaccine Co share price forecast for 2024?
The analyst consensus target price for shares in AIM Vaccine Co is HK$52.95. That is 541.84% above the last closing price of HK$8.25.
Analysts covering AIM Vaccine Co currently have a consensus Earnings Per Share (EPS) forecast of CNY0.63 for the next financial year.
What is the trend in the AIM Vaccine Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AIM Vaccine Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -11.84%.
As of the last closing price of HK$8.25, shares in AIM Vaccine Co were trading -59.86% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AIM Vaccine Co PE Ratio?
The AIM Vaccine Co PE ratio based on its reported earnings over the past 12 months is 9.43. The shares last closed at HK$8.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AIM Vaccine Co?
We do not have data on AIM Vaccine Co's directors